People

Governance grade: B- because Convatec has a genuinely independent, shareholder-facing board, but the new CEO and CFO still have light personal ownership and investors pushed back hard on the latest pay policy.

The People Running This Company

The management handoff was orderly under difficult circumstances: Karim Bitar took medical leave in August 2025, passed away in October 2025, and the board appointed the internal interim CEO/CFO pair permanently on 6 November 2025. That is a governance positive, but this is still a new executive configuration; the burden is now on Mason and Ryder to prove that the FISBE turnaround can become a durable growth model.

What They Get Paid

Director remuneration is disclosed in the remuneration report in GBP; the table and chart below convert those exact disclosed amounts at Convatec's 2025 average USD/GBP rate of 1.32 so the page currency matches Convatec's reporting currency.

The pay structure is performance-heavy rather than salary-heavy: 2025 bonus paid at 81.6% of maximum, free-cash-flow-to-equity paid only 32% of maximum, and the 2023 LTIP vested at 85.1% for Mason and Ryder. The concern is not a total absence of performance linkage; it is that the 2025 remuneration policy received only 67.0% support and the omnibus incentive plan only 75.6%, while 2026 LTIP maximums rise to 525% of salary for the CEO and 325% for the CFO.

Are They Aligned?

Control risk is low: there is one ordinary share class, no dual-class structure, no founder or promoter block, and the largest notified holders are clustered around 5%. That is good for minority shareholders, but it also means alignment depends on pay design, retained shares, and board discipline rather than a controlling owner with permanent capital at risk.

Insider activity is mixed but not alarming. Mason bought 100,000 shares in 2025 and Ryder bought 21,263; in March 2026 both sold shares only to meet tax and National Insurance on vested awards, with Mason retaining 326,457 net shares and Ryder retaining 31,053. The weakness is still economic exposure: Mason was at 161% of salary versus a 500% guideline at year-end 2025, and Ryder was at 91% versus 300%.

Capital allocation helps the alignment case. In 2025 Convatec completed a $301M buyback of 94.9M shares, raised the full-year dividend 13%, spent $121M on growth capex, and kept net debt at its 2.0x adjusted EBITDA target. The counterpoint is Triad/InnovaMatrix: the 2022 acquisition later took a $72M impairment after the CMS reimbursement reset, so the board still needs to prove bolt-on M&A discipline.

Skin-in-the-game score: 4/10. The governance structure is shareholder-friendly and recent personal purchases help, but executive ownership is still below guideline and much of the exposure is incentive-plan equity rather than outright owner capital.

Board Quality

Board quality is above average but not flawless. The board had nine directors and seven independent directors at year-end 2025; after Constantin Coussios stepped down on 30 April 2026, the current board is smaller and has a clearer gap in biomedical innovation oversight until he is replaced. The audit bench is strong, but Margaret Ewing's tenure and dual SID/Audit Chair role make her succession a real 2026 governance item.

The biggest board concern is not formal independence. It is whether the remuneration committee will respond to shareholder dissent and whether the board can keep challenging a management team that it has just promoted internally. The legacy FCA fine against former chair Christopher Gent for unlawful disclosure of inside information in 2018 is not a current-board issue, but it keeps market-abuse controls on the checklist.

The Verdict

The strongest positives are orderly internal succession, a majority-independent board, no controlling shareholder, no material related-party dealing, below-guideline dilution, and a capital allocation record that returned surplus cash while funding growth. The real concerns are light CEO/CFO ownership versus guidelines, a rich incentive policy with visible shareholder dissent, the need to replace lost innovation expertise after Coussios stepped down, and the pressure on the board to oversee M&A after the InnovaMatrix impairment.

An upgrade would come from Mason and Ryder building material outright ownership while delivering the 2026-2027 growth and margin targets without stretching pay discretion. A downgrade would come from another high-dissent remuneration vote, weak replacement of board innovation expertise, or further evidence that buybacks and bolt-on M&A are masking rather than compounding owner value.